Cargando…

Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy

Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajasekaran, Kamalakannan, Riese, Matthew J., Rao, Sridhar, Wang, Li, Thakar, Monica S., Sentman, Charles L., Malarkannan, Subramaniam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863891/
https://www.ncbi.nlm.nih.gov/pubmed/27242783
http://dx.doi.org/10.3389/fimmu.2016.00176
_version_ 1782431556838621184
author Rajasekaran, Kamalakannan
Riese, Matthew J.
Rao, Sridhar
Wang, Li
Thakar, Monica S.
Sentman, Charles L.
Malarkannan, Subramaniam
author_facet Rajasekaran, Kamalakannan
Riese, Matthew J.
Rao, Sridhar
Wang, Li
Thakar, Monica S.
Sentman, Charles L.
Malarkannan, Subramaniam
author_sort Rajasekaran, Kamalakannan
collection PubMed
description Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as “cytokine storm” and “cytokine-release syndrome” or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects.
format Online
Article
Text
id pubmed-4863891
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-48638912016-05-30 Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Rajasekaran, Kamalakannan Riese, Matthew J. Rao, Sridhar Wang, Li Thakar, Monica S. Sentman, Charles L. Malarkannan, Subramaniam Front Immunol Immunology Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as “cytokine storm” and “cytokine-release syndrome” or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects. Frontiers Media S.A. 2016-05-12 /pmc/articles/PMC4863891/ /pubmed/27242783 http://dx.doi.org/10.3389/fimmu.2016.00176 Text en Copyright © 2016 Rajasekaran, Riese, Rao, Wang, Thakar, Sentman and Malarkannan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rajasekaran, Kamalakannan
Riese, Matthew J.
Rao, Sridhar
Wang, Li
Thakar, Monica S.
Sentman, Charles L.
Malarkannan, Subramaniam
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title_full Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title_fullStr Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title_full_unstemmed Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title_short Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
title_sort signaling in effector lymphocytes: insights toward safer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863891/
https://www.ncbi.nlm.nih.gov/pubmed/27242783
http://dx.doi.org/10.3389/fimmu.2016.00176
work_keys_str_mv AT rajasekarankamalakannan signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT riesematthewj signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT raosridhar signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT wangli signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT thakarmonicas signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT sentmancharlesl signalingineffectorlymphocytesinsightstowardsaferimmunotherapy
AT malarkannansubramaniam signalingineffectorlymphocytesinsightstowardsaferimmunotherapy